1-3 of 3
Eno Inyang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Impact of Molecular Ontogeny on Hematological Recovery in AML Patients Treated with Hypomethylating Agent Plus Venetoclax Therapy

Josh Zhang, Shai O. Shimony, Yiwen Liu, Eno Inyang, Evan C. Chen, Luis E. Aguirre, Rebecca P. Bystrom, Benjamin Rolles, Richard M. Stone, Daniel J. DeAngelo, Emily Tiao, Maximilian Stahl
Journal: Blood
Blood (2024) 144 (Supplement 1): 5175.
https://doi.org/10.1182/blood-2024-200358
Published: 2024
Journal Articles

Decreasing Costs and Clinic Wait Time While Maintaining Safety for Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) for Multiple Myeloma

Eno Inyang, Anil Aktas-Samur, Nikhil C. Munshi, Houry Leblebjian
Journal: Blood
Blood (2021) 138 (Supplement 1): 666.
https://doi.org/10.1182/blood-2021-146605
Published: 2021
Journal Articles

Continuous Pre-Dose Assessment of Laboratory Parameters Is Not Required for Multiple Myeloma Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD)

Eno Inyang, PharmD, BCPS, Nikhil C. Munshi, MD, Anil Aktas-Samur, PhD, Houry Leblebjian, PharmD, BCOP
Journal: Blood
Blood (2020) 136 (Supplement 1): 11.
https://doi.org/10.1182/blood-2020-136342
Published: 2020